Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 1, 1997, Pages 1-8

  Stewart, David J ^a,b   Cripps, M Christine ^a,b   Goel, Rakesh ^a,b   Dahrouge, Simone ^a   Yau, Jonathan ^a,b   Tomiak, Eva ^a,b   Huan, Susan ^a,b   Soltys, Kathy ^a   Prosser, Ann ^a   Davies, Ross A ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Chemotherapy; Cyclo sporin; Dipyridamole; Epirubicin resistance; Ketoconazole; Metronidazole; Modulators; Tamoxifen

Indexed keywords

CYCLOSPORIN; DIPYRIDAMOLE; EPIRUBICIN; KETOCONAZOLE; METRONIDAZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MIXTURE; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PILOT STUDY; PRIORITY JOURNAL; VOMITING;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTITRICHOMONAL AGENTS; CYCLOSPORINE; DIPYRIDAMOLE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOCONAZOLE; MALE; METRONIDAZOLE; MIDDLE AGED; NEOPLASMS; PILOT PROJECTS; TAMOXIFEN; VASODILATOR AGENTS;

EID: 6844241959     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050700     Document Type: Article

References (83)

1. Harker WG, Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell lines MES-SA. Cancer Res 45: 4091-4096
2. Ishida Y, Ohtsu T, Hamada H, Sugimoto Y, Tobinai K, Minato K, Tsuruo T, Shimoyama M (1989) Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody. MRK16. Jpn J Cancer Res 80: 1006-1013
3. Tebbi CK, Chervinsky D, Baker RM (1991) Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporin A and dipyridamole. J Cell Physiol 148: 464-471
4. Posada JA, McKeegan EM, Worthington KF, Morin MH, Jaken S, Tritton TR (1989) Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. Cancer Commun 1: 285-292
5. Deffie AM, Bosman DJ, Goldenberg GJ (1989) Evidence for a mutant allele of the gene for DNA topoisomerase II in adriamycin-resistant P388 murine leukemia cells. Cancer Res 49: 6879-6882
6. Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 49: 58-62
7. Zijlstra JG, de Vries EGE, Mulder NH (1987) Multifactorial drug resistance in adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780-1784
8. Stewart DJ, Evans WK (1989) Non-chemotherapeutic agents which potentiate chemotherapy efficacy. Cancer Treat Rev 16: 1-40
9. Leyland-Jones B, Dalton W, Fisher GA, Sikic B (1993) Reversal of multidrug resistance to cancer chemotherapy. Cancer 72: 3484-3488
10. Goodman GE, Yen YP, Cox TC, Crowley J (1987) Effect of verapamil on in vitro eytotoxicity of adriamycin and vinblastine in human tumor cells. Cancer Res 47: 2295-2304
11. Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M, Kuwano M (1986) Circumvention of multi-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J Natl Cancer Inst 76: 839-844
12. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S, Sakurai Y (1984) Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 44: 4303-4307
13. Twentyman PR, Fox NE, White DJG (1987) Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 56: 55-57
14. Ayesh S, Shao YM, Stein WD (1996) Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316: 8-18
15. Murray D, Meyn RE (1984) Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo. Br J Cancer 50: 801-808
16. Roizin-Towle E, Hall EJ, Pirro JP (1986) Oxygen dependence for chemosensitization by misonidazole. Br J Cancer 54:919-924
17. Taylor YC, Sawyer JM, Hsu B, Brown JM (1984) Mechanisms of melphalan crosslink enhancement by misonidazole pretreatment. Int J Radiat Oncol Biol Phys 10: 1603-1607
18. Mahood JS, Willson RL (1981) Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate. Br J Cancer 43: 350-354
19. Rowlands MG, Budworth J, Jarman M, Hardcastle IR, McCague R, Gescher A (1995) Comparison between inhibition of protein kinase C and antagonism of calmodulin by tamoxifen analogues. Biochem Pharmacol 50: 723-726
20. Rochlitz CF, Damon LE, Cadman EC (1987) Influence of ketoconazole on intracellular VP-16 retention in L1210 cells. Proc Am Assoc Cancer Res 28: 413
21. Siegsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I, Gottesman MM (1994) Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151: 485-491
22. Ramu A, Spanier R, Rahamimoff H, Fuks Z (1984) Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukemia cells. Br J Cancer 50: 501-507
23. Volm M, Kastei M, Mattern J, Efferth T (1993) Expression of resistance factors (p-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to prolooncogene products in renal cell carcinomas. Cancer 71: 3981-3987
24. Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 66: 833-839
25. Robert J (1994) Proposals for concomitant use of several modulators of multidrug resistance in clinics. Anticancer Res 14: 2371-2374
26. Kim JH, Chung JB, Park IS, Kim BS, Yoo NC, Choi JH, Roh JK, Kim HS, Kwon OH, Lee KS, et al (1993) Combined use of tamoxifen, cyclosporin A, and verapamil for modulating resistance in human hepatocellular carcinoma cell lines. Yonsei Med J 34: 35-44
27. Lyubimov E, Lan L-B, Pashinsky I, Ayesh S, Stein WD (1995) Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Anticancer Drugs 6: 727-735
28. Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE (1991) Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model, Blood 77: 348-354
29. Ishida Y, Shimada Y, Shimoyama M (1990) Synergistic effect of cyclosporin A and verapamil on overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells. Jap J Cancer Res 81: 834-841
30. Hu XF, Martin TJ, Bell DR, de Luise M, Zalcbert JR (1990) Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957
31. Osann K, Sweet P, Slater LM (1992) Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro. Cancer Chemother Pharmacol 30: 152-154
32. Ross DD, Wooten PJ, Tong Y, Cornblatt B, Levy C, Sridhara R, Lee EJ, Schiffer CA (1994) Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells in cyclosporin A and cremophor EL. Blood 83: 1337-1347
33. Lai S-L, Hwang J, Perng R-P, Whang-Peng J (1995) Modulation of cisplalin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncol Res 7: 31-38
34. Brooks SE, Korbut TT, Dupuis NP, Holden SA, Teicher BA (1995) Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin. Cancer Chemother Pharmacol 36: 431-438
35. Goel R, Stewart DJ (1992) Phase I study of epirubicin plus biochemical modulators. Proc Am Soc Clin Oncol 11: 133
36. Stewart DJ, Goel R, Huan SD, Cripps MC, Yau JC, Soltys K, Prosser A, Bourcier J, Paul M, Evans WK, Gallant G (1993) Etoposide plus multiple resistance modulators. Proc Am Soc Clin Oncol 12: 152
37. Stewart DJ, Goel R, Verma S, Perrault D, Cripps C (1992) Carboplatin plus multiple resistance modulators. Proc Am Assoc Cancer Res 33: 235
38. Stewart DJ, Dahrouge S, Agboola O, Girard A (1997) Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas. J Neurooncol 32: 161-168
39. Gillis MC (ed) (1996) Compendium of pharmaceuticals and specialties, 31st ed. Canadian Pharmaceutical Association, Ottawa
40. Fardel O, Lecureur V, Guillouzo A (1993) Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. FEBS Lett 327: 189-193
41. Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT (1993) Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 133: 521-528
42. Coyle P, Philcox JC, Rofe AM (1993) Corticosterone enhances the zinc and interleukin-6-mediated induction of metallothionein in cultured rat hepatocytes. J Nutr 123: 1464-1470
43. Beksac M, Akan H, Koc H, Ilhan O, Erturk S, Guneyli A, Ikizunal Y, Sardas OS (1992) P-glycoprotein expression in refractory hematological neoplasms and circumvention of resistance with verapamil or cyclosporin A containing protocols. Med Oncol Tumor Pharmacother 9: 101-105
44. Manzano RG, Alonso G, Foncillas JG, Brugarolas A (1993) Cyclosporin A (CsA) plus doxorubicin (dox) containing chemotherapy in adult anthracycline resistant solid tumors (ARST): a phase I clinical study. Proc Am Soc Clin Oncol 12: 146
45. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W (1993) Phase I/II trial of cyclosporin as a chemotherapy-resistant modifier in acute leukemia. J Clin Oncol 11: 1652-1660
46. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842
47. Subar M, Green MD, Fischer P (1986) Phase I study of daily oral methotrexate with concurrent dipyridamole (DP) for inhibition of salvage pathway 'rescue'. Proc Am Soc Clin Oncol 5:42
48. Willson JK, Fischer PH, Remick SC, Tutsch KJD, Grem JL, Nieting L, Alberti D, Bruggink J, Trump DL (1989) Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans. Cancer Res 49: 1866-1870
49. Woodcock TM, Gentile PS, Seeger J, Epremian BE, Hamm JT, Sheth SP, Sherrille EH, Kellihan MJ, Lalley KA, Allegra JC (1987) A phase I study of dipyridamole and methotrexate (MTX). Proc Am Soc Clin Oncol 6: 29
50. Higano CS, Livingston RB (1989) Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial. Cancer Chemother Pharmacol 23: 259-262
51. Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ (1994) A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. Am J Clin Oncol 17: 10-13
52. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A (1990) Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. A phase I/II study. Cancer 65: 1895-1902
53. Stewart DJ, Futter N, Irvine A, Danjoux C, Moors D (1987) Mitomycin-C and metronidazole in the treatment of advanced renal cell carcinoma. Am J Clin Oncol 10: 520-522
54. Stewart DJ, Maroun JA, Lefebvre B, Heringer R, Crook AF (1985) Mitomycin-C plus metronidazole in advanced carcinoma of the breast. Breast Cancer Res Treat 5: 189-194
55. Stewart DJ, Maroun JA, Young V, Crook AF, Hopkins HS, Yan RC, Richard MT, Hugenholtz H, Belanger R, Heringer R, Lefebvre B, Laframboise G (1983) Feasibility study of combining metronidazole with chemotherapy. J Clin Oncol 1: 17-23
56. Stewart DJ, Benoit B, Richard MT, Hugenholtz H, Dennery J, Russell N, Peterson E, Grahovac Z, Belanger G, Maroun JA, Young V (1984) Treatment of malignant gliomas in adults with BCNU plus metronidazole. J Neurooncol 2: 53-58
57. Raaphorst GP, Yang DP, Grewaal D, Stewart D, Goel R, Ng CE (1995) Analysis of mechanisms of cisplatin resistance in three pairs of human tumour cell lines expressing normal and resistant responses to cisplatin. Oncol Rep 2: 1037-1043
58. Robert J (1993) Epirubicin: clinical pharmacology and dose-effect relationship. Drugs 45: 20-30
59. Launchbury AP, Habboubi N (1993) Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197-228
60. Bellamy WT, Peng YM, Odeleye A, Ellsworth L, Xu MJ, Grogan TM, Weinstein RS (1995) Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anticancer Drugs 6: 736-743
61. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN et al (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
62. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI (1993) Clinical trial of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72: 3502-3514
63. Lee FYF, Workman P (1986) Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumor activity and acute toxicity of selected nitrogen mustards. Cancer Chemother Pharmacol 17: 30-37
64. Bennett JE (1990) Antimicrobial agents. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 8th edn. Pergamon Press, New York, p1170
65. Back DJ, Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32: 624-626
66. Zylber-Katz E, Rubinger D, Berlatzky Y (1988) Cyclosporine interactions with metronidazole and cimetidine. Drug Intell Clin Pharm 22: 504-505
67. Lake KD (1991) Management of drug interactions with cyclosporine. Pharmacotherapy 11: 110S-118S
68. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P (1993) Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837-4842
69. Sotomatsu M, Yugami S-I, Shitara T, Kuroume T. (1993) Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells. Am J Hematol 43: 251-255
70. Sonnoveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259
71. Sikic BL (1993) Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635
72. Chan HSL, Koren G, Thorner PS, Verjee Z, Haddad G, Giesbrecht E, Greenberg ML, Ling V, Gallie BL (1992) Reversal of multidrug resistance (MDR) in retinoblastoma (RB) by cyclosporin A (CsA). Proc Am Soc Clin Oncol 11: 375
73. Stiff P, Bayer R, Tan S, Camarda J, Sosman J, Peace D, Kinch L, Rad N, Loutfi S (1995) High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Clin Cancer Res 1: 1495-1502
74. Manetta A, Boyle J, Berman M, DiSaia PJ, Lentz S, Liao SY, Mutch D, Slater L (1994) Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer 73: 196-199
75. Stewart DJ, Cripps MC, Lamothe A, Laframboise G, Odell P, Gerin-Lajoie J (1993) Doxorubicin plus metronidazole in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 16: 113-116
76. Baradakji Z, Jolivet J, Langelier, Y, Besner JG, Ayoub J (1986) 5-fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Cancer Chemother Pharmacol 18: 140-144
77. Dalley D, Dalley D, Brigham B (1993) Phase I/II study of oral etoposide and modulation of drug resistance with ketoconazole (KCZ) in small cell lung cancer (SCLC). Fourth International Congress on Anti-Cancer Chemotherapy, Paris, 1993, p85
78. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting ASTh, Seynaeve C, Stoter G, Nooter K (1991) A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64: 361-364
79. Wishart GC, Harnett A, Kerr DH, Paul J, Machem MA, Soukop M, Leonard RCF, Kayer SB (1993) A randomised placebo controlled trial of quinidine as a resistance modulator in patients with advanced breast cancer treated with epirubicin. Proc Am Soc Clin Oncol 12: 58
80. Stewart DJ, Raaphorst P, Yau J, Beaubien A (1996) Active vs passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14: 115-130
81. Stewart DJ, Evans WK, Logan D (1994) Addition of pentoxifylline plus nifedipine to chemotherapy in patients with cisplatin-resistant cancers of the lung and other sites. Am J Clin Oncol 17: 313-316
82. Stewart DJ, Goel R, Gertler S, Huan S, Yau J, Tomiak E, Cripps C, Prosser A, Soltys K (1996) Multiple chemotherapy drugs with differing mechanisms of action to overcome passive resistance. Proc Am Soc Clin Oncol 15: 405
83. Goel R, Stewart DJ (1996) Phase I study of alternating cycles of high dose combination chemotherapy with different mechanisms of action to overcome drug resistance. Proc Am Soc Clin Oncol 15: 493